| Recruitment status | No longer recruiting |
| Unique ID issued by UMIN | UMIN000022321 |
| Receipt No. | R000025719 |
| Official scientific title of the study | International Retrospective Cohort Study of Conversion Therapy (Adjuvant surgery) for Stage IV Gastric Cancer 1 |
| Date of disclosure of the study information | 2016/05/16 |
| Last modified on | 2018/11/26 (Ver. 6) |
| Basic information | |||
| Official scientific title of the study | International Retrospective Cohort Study of Conversion Therapy (Adjuvant surgery) for Stage IV Gastric Cancer 1 | ||
| Title of the study (Brief title) | International Retrospective Cohort Study of Conversion Therapy (Adjuvant surgery) for Stage IV Gastric Cancer 1 (CONVO-GC-1) | ||
| Region |
|
||
| Condition | ||
| Condition | StageIV gastric cancer | |
| Classification by specialty |
|
|
| Classification by malignancy | Malignancy | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | The aim of the study is to clarify the present information of conversion therapy of stage IV gastric cancer in Asian counties, to investigate the feasibility of the therapy and to collect the baseline data for future analysis to clarify the role of the therapy. |
| Basic objectives2 | Safety |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | The rate of operative complications after conversion therapy |
| Key secondary outcomes | Overall Survival(OS), Relapse free survival(RFS), Response rate, and Histological response |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | To clarify the meaning of conversion therapy, we need to collect all stage IV gastric cancer patients who underwent operation with successful chemoradiationtherapy.
1. Histologically proven primary gastric adenocarcinoma. 2. Stage IV gastric cancer patients initially regarded as non-curably resectable but with successful chemotherapy, regarded as curably resectable (R0), then underwent radical operation (including metastasectomy). 3. Stage IV gastric cancer patients initially regarded as resectable, underwent radical operation after chemotherapy (neoadjuvant case). 4. Stage IV gastric cancer patients with peritoneal dissemination or positive cytology by staging laparoscopy or laparotomy but with successful chemotherapy, then underwent radical operation, or patients who underwent gastrectomy irrespective of chemotherapy. |
|||
| Key exclusion criteria | None | |||
| Target sample size | 900 | |||
| Research contact person | |
| Name of lead principal investigator | Kazuhiro YOSHIDA |
| Organization | Gifu University School of Medicine |
| Division name | Department of Surgical Oncology |
| Address | Yanagido 1-1, Gifu-city, Gifu |
| TEL | 058-230-6235 |
| kyoshida@gifu-u.ac.jp | |
| Public contact | |
| Name of contact person | Mami SAKURAI |
| Organization | Federation of Asian Clinical Oncology (FACO) |
| Division name | Tokyo Office |
| Address | Shinkawa Bldg. 2F, 2-13-10, Shinkawa, Chu-ku, Tokyo 104-0033 Japan |
| TEL | 03-5542-0546 |
| Homepage URL | |
| faco-office@jsco.or.jp | |
| Sponsor | |
| Institute | FACO(Federation of Asian Clinical Oncology) |
| Institute | |
| Department | |
| Funding Source | |
| Organization | FACO(Federation of Asian Clinical Oncology) |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | No longer recruiting | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | Questionnaire survey (Retrospective cohort study) for patients completed adjuvant surgery from 01Jan2001 to 31Dec2014.
Surveillance items of clinical data I. Sequence of diagnosis and treatment II. Patients' background information at diagnosis, Tumor status: Pathological diagnosis, Lauren classification, Depth of tumor, Lymph node metastasis, Liver metastasis, Peritoneal dissemination, Tumor diameter, Location of metastasis, Diagnostic staging laparoscopy, Diagnostic method for peritoneal dissemination, Other cancers, Complication and comorbidity, Having target lesion or not, HER2 status. III. Treatment status of chemotherapy and radiation therapy: Regimen, number of cycle, the reason of discontinuation, Dose and period of radiation therapy. IV. Evaluation of Response: Overall response evaluated by RECIST version 1.1. V. Surgical and Pathological Information: Type of tumor, Histological type, tumor diameter, Lymph node metastasis, number of metastasis and dissected lymph node, distant metastasis, Liver metastasis, Peritoneal dissemination, Peritoneal lavage cytology, Proximal and distal margin, Residual tumor, Reason for conversion therapy, Date of surgery, Operation time, Estimated blood loss, Volume of blood transfusion, mode of operation, Extension of lymph node dissection, Combined organ resection, Histological response. VI. Postoperative Complications: Wound infection, Thromboembolism, Anastomotic leakage, Intraperitoneal abscess, Pancraticfistula, Postoperative pneumonia, others. VII. Postoperative treatment status: Regimen of chemotherapy, number of cycle, Reason of discontinuation, dose and period of radiation therapy, Reason of no treatment. VIII. Confirmation of outcome: Date last known to be alive or date of death, Cause of death, Date of tumor relapse after curative resection, recurrent site, Survival status, Method of confirmation of outcome, Tumor relapse/recurrence. |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000025719 |